CRISPR/Cas9-mediated genome editing can be used to remove genes that encode inhibitory T-cell surface receptors, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), to increase the effectiveness of T-cell-based immunotherapy in treating cancer. Here, PDCD1 is linked to cancer.